Skip to content

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. („Dyadic“ or the „Company“) (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute… Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – The post Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv appeared first on Bio Tech Winners. Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences The post Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 appeared first on Bio Tech Winners. Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise The post Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer appeared first on Bio Tech Winners. Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Compact photoacoustic sensing instrument for breast tissue characterization

In a recent study published in the Journal of Biomedical Optics, researchers from the Indian Institute of Technology Indore unveiled a groundbreaking advancement—a compact and cost-effective PA sensing instrument designed specifically for biomedical tissue diagnosis. This proof-of-concept study employs low-cost diode laser. It represents a crucial step towards bridging the gap between laboratory research and clinical applications. The newly developed instrument integrates multiple laser diodes within a compact casing, alongside a custom-built pulsed current supply unit. This setup ensures efficient PA excitation, generating precise 25 nanosecond pulses at a frequency of 20 kHz. Subsequent data analysis involved calculating frequency spectra to quantitatively assess tissue properties. The results revealed distinct spectral patterns corresponding to different tissue types. For instance, fibrocystic breast disease exhibited a dominant frequency peak around 1.60 MHz, indicative of increased tissue density due to heightened glandular and stromal… 

more »Compact photoacoustic sensing instrument for breast tissue characterization

NIH launches research network to evaluate emerging cancer screening technologies

The National Institutes of Health (NIH) has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot? by investigating how to identify cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network. In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials. MCDs are blood tests that can screen for several types of cancers. The study will enroll up to 24,000 people to inform the design of a much larger randomized controlled trial. This larger trial will evaluate whether the benefits… 

more »NIH launches research network to evaluate emerging cancer screening technologies

Bavarian Nordic delivered record financial results in 2023

COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The post Bavarian Nordic delivered record financial results in 2023 appeared first on Bio Tech Winners. Bavarian Nordic delivered record financial results in 2023

Researchers test "wonder material" on humans for the first time

Will it soon be possible to inhale medicine easily? Researchers have now successfully tested a potentially revolutionary nanomaterial on humans for the first time. They describe it as a "wonder material." Tests with face masks The scientists led by Dr. Mark Miller from the Center for Cardiovascular Science at the University of Edinburgh used for this first study, published in the journal Nature, [...] Researchers test "wonder material" safely on humans for the first time

IQWiG study: AMNOG takes effect with a time delay

For orphan drugs, the political goal of aligning the price with the additional benefit is only achieved through the subsequent regular benefit assessment. This is shown by a current IQWiG analysis. To promote the development of drugs for rare diseases (orphan drugs) despite economic risks, they are treated preferentially in Germany: New orphan drugs only have to demonstrate an additional benefit compared to the appropriate comparator therapy if they exceed the annual sales limit of 30 million euros (up to November 2022: 50 million euros). Previously, their additional benefit is considered proven, and the Gemeinsame Bundesausschuss (G-BA) merely quantifies the extent of the additional benefit based on the (marketing authorization) documents. If, within the scope of this "limited assessment," no classification into the categories "minor," "considerable," or "substantial" is possible, the G-BA must still attest a "non-quantifiable" additional benefit to the active ingredient. The Institute for Quality and Efficiency in Health Care (IQWiG) has now analyzed the impact of this preferential treatment of orphan drugs on the prices of...

more »IQWiG study: AMNOG takes effect with a time delay